Business
PRELIMINARY RESULTS FOR THE YEAR ENDED 31 DEC 2016
PRELIMINARY RESULTS FOR THE YEAR ENDED 31 DEC 2016.
About this update from Oxford Biomedica Plc
[{"type":"text","content":"\n \nRNS Number : 6201Z Oxford Biomedica PLC 16 March 2017 \n\n \n OXFORD BIOMEDICA PLC \nPRELIMINARY RESULTS FOR THE YEAR ENDED 31 DECEMBER 2016\n \nOxford, UK - 16 March 2017: Oxford BioMedica plc (LSE: OXB), (\"OXB\" or \"the Group\") a leading gene and cell therapy group, today announces preliminary results for the twelve months ended 31 December 2016.\n \nHIGHLIGHTS (INCLUDING POST-PERIOD END)\n \nOPERATIONAL\nLeading LentiVector® delivery platform for gene and cell therapy partnerships\n- Novartis collaboration progressing well with blockbuster potential product CTL019 close to market and second undisclosed CAR-T programme\n- Strategic alliance established with Orchard Therapeutics to develop and supply lentiviral vectors for ex vivo treatments\n- Immune Design collaboration expanded, including licence to use lentiviral vector-based products for in vivo treatments for cancer\n- New R&D collaboration with Green Cross LabCell focused on gene modified natural killer (NK) cell-based therapies\n- 200 litre bioreactor production process established at commercial scale with potential to increase yield substantially and reduce cost of a patient dose\n- Transgene Repression In Vector Production (TRiP) system developed to enhance the production titres of a broad range of gene therapy vectors\n \nState-of-the-art bioprocessing and laboratory facilities\n- Major capacity expansion completed\n- MHRA approval granted for GMP vector manufacture\n- Vector production volume increased by 54% compared with 2015\n \nProgress with proprietary product development\n- Ground-breaking long-term result...